We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Hematologic Abnormalities Found in HIV-Infected Children

By LabMedica International staff writers
Posted on 22 Aug 2017
In both antiretroviral-treated and untreated individuals, different types of hematological abnormalities have been documented, the most important being pancytopenia. More...
These changes are related with increased risk of morbidity and mortality.

Anemia is a common finding in patients with human immunodeficiency viral (HIV) infection and it is more prevalent in patients with advanced retroviral infection. Its prevalence ranges from 11.7% to 92% depending on the stage of HIV disease, sex, age, pregnancy status, and presence of opportunistic infections (OIs).

Scientists at the University of Gondar (Ethiopia) conducted a cross-sectional study was conducted from June 1 to August 30, 2015 on 222 HIV-infected children. All children less than15 years of age who took antiretroviral therapy (ART) for more than six months were considered for inclusion in the study. Anemia, neutropenia and thrombocytopenia were defined based on World Health Organization (WHO, Geneva, Switzerland) grading of hematologic toxicity. Accordingly, anemia was defined as hemoglobin (Hgb) concentration equal to or less than 10.5 g/dL for all children and further severity was also classified. Neutropenia was defined as absolute neutrophil count (ANC) of less than 1,500/mm3, and any increased severity further classified.

The investigators reported that the median age of study subjects was 10 years and 74.3% of the study subjects received ART for more than a year. The median of CD4 count before ART was 490 cells/mm3 and this increased to 663 cells/ mm3 after ART. The median of hemoglobin before ART was 11.5 mg/dL which increased after ART to 13 mg/dL and the prevalence of anemia was 42.8% before and 18.9% after ART initiation. The median of absolute neutrophil count before ART was 3×103/mm3 and after ART remained practically almost unchanged. Thrombocytopenia was observed in 8.1% of the study patients and decreased to 1.8% after treatment with ARV drugs.

The authors concluded that anemia was the top abnormality identified, followed by thrombocytopenia and leukopenia and after ART initiation, and there was a significant improvement of the hematologic profile among the pediatric population studied. The study was published on August 4, 2017, in the Journal of Blood Medicine.

Related Links:
University of Gondar
World Health Organization


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
hCG Whole Blood Pregnancy Test
VEDALAB hCG-CHECK-1
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.